Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Medtronic
Moodys
Colorcon
AstraZeneca

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

Claims for Patent: 6,057,156

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,057,156
Title: Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
Abstract:Enzymatic nucleic acid molecules which cleave EGFR RNA.
Inventor(s): Akhtar; Saghir (Birmingham, GB), Fell; Patricia (Wythall, GB), McSwiggen; James A. (Boulder, CO)
Assignee: Robozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:08/985,162
Patent Claims:1. An enzymatic nucleic acid molecule which specifically cleaves RNA derived from an epidermal growth factor receptor (EGFR) gene encoding an EGFR with a functional extracellular domain and a functional intracellular domain.

2. The enzymatic nucleic acid molecule of claim 1, wherein said nucleic acid molecule is in a hairpin motif.

3. The enzymatic nucleic acid molecule of claim 1, wherein said nucleic acid molecule is in a hammerhead motif.

4. The enzymatic nucleic acid molecule of claim 3, wherein said nucleic acid molecule comprises a stem II region of length greater than or equal to 2 base pairs.

5. The enzymatic nucleic acid molecule of claim 3, wherein the binding arms of said nucleic acid molecule comprises sequences complementary to any of SEQ ID NOs 1-823.

6. The enzymatic nucleic molecule of claim 2, wherein the binding arms of said nucleic acid molecule comprises sequences complementary to any of SEQ ID NOs 1759-1870.

7. The enzymatic nucleic acid molecule of claim 2, wherein said nucleic haipin motif consists essentially of any ribozyme sequence shown as SEQ ID NOs 1647-1758.

8. The enzymatic nucleic molecule of claim 3, wherein said nucleic hammerhead motif consists essentially of any ribozyme sequence shown as SEQ ID NOs 824-1646.

9. The enzymatic nucleic acid molecule of claim 1, wherein said nucleic acid molecule is in a hepatitis delta virus, VS nucleic acid, group I intron, Group II intron, or RNase P nucleic acid motif.

10. The enzymatic nucleic acid molecule of claim 1, wherein said nucleic acid comprises between 12 and 100 bases complementary to said RNA.

11. The enzymatic nucleic acid molecule of claim 1, wherein said nucleic acid comprises between 14 and 24 bases complementary to said mRNA.

12. A mammalian cell including an enzymatic nucleic acid molecule of claim 1, wherein said mammalian cell is not a human.

13. The cell of claim 12, wherein said cell is a human cell.

14. An expression vector comprising nucleic acid sequence encoding at least one of the enzymatic nucleic acid molecule of claim 1, in a manner which allows expression of that enzymatic nucleic acid molecule.

15. A mammalian cell including an expression vector of claim 14, wherein said mammalian cell is not a human.

16. The cell of claim 15, wherein said cell is a human cell.

17. A composition comprising the enzymatic nucleic acid molecule of claim 1.

18. The enzymatic nucleic acid molecule of claim 3, wherein said nucleic acid molecule comprises at least five ribose residues, and wherein said nucleic acid comprises phosphorothioate linkages at at least three of the 5' terminal nucleotides, and wherein said nucleic acid comprises a 2'-C-allyl modification at position No. 4 of said nucleic acid, and wherein said nucleic acid comprises at least ten 2'-O-methyl modifications, and wherein said nucleic acid comprises a 3'- end modification.

19. The enzymatic nucleic acid of claim 18, wherein said nucleic acid comprises a 3'--3' linked inverted ribose moiety at said 3' end.

20. The enzymatic nucleic acid molecule of claim 3, wherein said nucleic acid molecule comprises at least five ribose residues, and wherein said nucleic acid molecule comprises phosphorothioate linkages at at least three of the 5' terminal nucleotides, and wherein said nucleic acid comprises a 2'-amino modification at position No. 4 and/or at position No. 7 of said nucleic acid molcule, wherein said nucleic acid molcule comprises at least ten 2'-O-methyl modifications, and wherein said nucleic acid comprises a 3'-end modification.

21. The enzymatic nucleic acid molecule of claim 3, wherein said nucleic acid molecule comprises at least five ribose residues, and wherein said nucleic acid molecule comprises phosphorothioate linkages at at least three of the 5' terminal nucleotides, and wherein said nucleic acid molecule comprises an abasic substitution at position No. 4 and/or at position No. 7 of said nucleic acid molecule, wherein said nucleic acid comprises at least ten 2'-O-methyl modifications, and wherein said nucleic acid molecule comprises a 3'-end modification.

22. The enzymatic nucleic acid molecule of claim 3, wherein said nucleic acid molecule comprises of at least five ribose residues, and wherein said nucleic acid comprises phosphorothioate linkages at at least three of the 5' terminal nucleotides, and wherein said nucleic acid molecule comprises a 6-methyl uridine substitution at position No. 4 and/or at position No. 7 of said nucleic acid molecule, wherein said nucleic acid molecule comprises at least ten 2'-O-methyl modifications, and wherein said nucleic acid molecule comprises a 3' end modification.

23. An enzymatic nucleic acid molecule which specifically cleaves RNA derived from an epidermal growth factor receptor (EGFR) gene encoding an EGFR which does not contain a deletion in its extracellular domain.

24. The enzymatic nucleic acid molecule of claim 23, wherein said nucleic acid molecule is in a hairpin motif.

25. The enzymatic nucleic acid molecule of claim 23, wherein said nucleic acid molecule is in a hammerhead motif.

26. The enzymatic nucleic acid molecule of claim 25, wherein said nucleic acid molecule comprises a stem II region of length greater than or equal to 2 base pairs.

27. The enzymatic nucleic acid molecule of claim 25, wherein the binding arms of said nucleic acid molecule comprises sequences complementary to any of SEQ ID Nos 1-823.

28. The enzymatic nucleic acid molecule of claim 24, wherein the binding arms of said nucleic acid molecule comprises sequences complementary to any of SEQ ID Nos 1759-1870.

29. The enzymatic nucleic acid molecule of claim 24, wherein said nucleic hairpin motif consists essentially of any ribozyme sequence shown as SEQ ID Nos 1647-1758.

30. The enzymatic nucleic acid molecule of claim 25, wherein said nucleic hammerhead motif consists essentially of any ribozyme sequence shown as SEQ ID Nos 824-1646.

31. The enzymatic nucleic acid molecule of claim 23, wherein said nucleic acid molecule is in a hepatitis delta virus, VS nucleic acid, Group I intron, Group II intron, or Rnase P nucleic acid motif.

32. The enzymatic nucleic acid molecule of claim 23, wherein said nucleic acid comprises between 12 and 100 bases complementary to said RNA.

33. The enzymatic nucleic acid molecule of claim 23, wherein said nucleic acid comprises between 14 and 24 bases complementary to said mRNA.

34. A mammalian cell including an enzymatic nucleic acid molecule of claim 23, wherein said mammalian cell is not a human.

35. The cell of claim 34, wherein said cell is a human cell.

36. An expression vector comprising nucleic acid sequence encoding at least one of the enzymatic nucleic acid molecule of claim 23, in a manner which allows expression of that enzymatic nucleic acid molecule.

37. A mammalian cell including an expression vector of claim 36, wherein said mammalian cell is not a human.

38. The cell of claim 37, wherein said cell is a human cell.

39. The enzymatic nucleic acid molecule of claim 25, wherein said nucleic acid comprises at least five ribose residues, and wherein said nucleic acid comprises phosphorothioate linkages at least three of the 5' terminal nucleotides, and wherein said nucleic acid comprises a 2'-C-ally modification at position No. 4 of said nucleic acid, and wherein said nucleic acid comprises at least ten 2'-O-methyl modifications, and wherein said nucleic acid comprises a 3'-end modification.

40. The enzymatic nucleic acid of claim 39, wherein said nucleic acid comprises a 3'-3' linked inverted ribose moiety at said 3' end.

41. The enzymatic nucleic acid molecule of claim 25, wherein said nucleic acid molecule comprises at least five ribose residues, and wherein said nucleic acid molecule comprises phosphorothioate linkages at least three of the 5' terminal nucleotides, and wherein said nucleic acid comprises 2'-amino modification at position No. 4 and/or at position No. 7 of said nucleic acid molecule, wherein said nucleic acid comprises a 2'-O-methyl modifications, and wherein said nucleic acid comprises a 3'-end modification.

42. The enzymatic nucleic acid molecule of claim 25, wherein said nucleic acid molecule comprises at least five ribose residues, and wherein said nucleic acid molecule comprises phosphorothioate linkages at least three of the 5' terminal nucleotides, and wherein said nucleic acid molecule comprises an abasic substitution at position No. 4 and/or at position No. 7 of said nucleic acid molecule, wherein said nucleic acid comprises at least ten 2'-O-methyl modifications, and wherein said nucleic acid molecule comprises a 3'-end modification.

43. The enzymatic nucleic acid molecule of claim 25, wherein said nucleic acid molecule comprises of at least five ribose residues, and wherein said nucleic acid comprises phosphorothioate linkages at least three of the 5' terminal nucleotides, and wherein said nucleic acid molecule comprises a 6-methyl uridine substitution at position No. 4 and/or position No. 7 of said nucleic acid molecule, wherein said nucleic acid molecule comprises at least ten 2'-O-methyl modifications, and wherein said nucleic acid molecule comprises a 3' end modification.

44. A composition comprising the enzymatic nucleic acid molecule of claim 23.

Details for Patent 6,057,156

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Robozyme Pharmaceuticals, Inc. (Boulder, CO) 2017-01-31 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Robozyme Pharmaceuticals, Inc. (Boulder, CO) 2017-01-31 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Robozyme Pharmaceuticals, Inc. (Boulder, CO) 2017-01-31 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 6,057,156

Country Patent Number Publication Date
United States of America 2001006801 Jul 05, 2001
United States of America 2002013458 Jan 31, 2002
United States of America 2002082225 Jun 27, 2002
United States of America 2002192685 Dec 19, 2002
United States of America 2002193579 Dec 19, 2002
United States of America 2002197684 Dec 26, 2002
United States of America 2003003469 Jan 02, 2003
>Country >Patent Number >Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Moodys
Merck
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.